FDA declines clear stance on foreign imports

The Food and Drug Administration was asked a simple question and refused to give a simple answer. A patient-advocacy group had asked the agency to spell out how the law applies to alternative funding programs, or AFPs, which steer patients to cheaper medicines from overseas when their health plans will not cover high-cost drugs. On March 27, the FDA said it shared the group’s safety concerns, but declined to issue specific guidance because doing so was “not warranted at this time” and would not be an efficient use of resources. That left the central problem in place: the agency says these imports can violate the law, but it still will not draw a bright line around the practice (cnbc.com). That matters because U.S. drug import law is not vague in the broad sense. The default rule is that importing unapproved prescription drugs, including foreign-market versions of FDA-approved medicines, is generally prohibited, with only narrow exceptions. Congress did create one formal pathway, Section 804 of the Food, Drug, and Cosmetic Act, but that pathway is tightly limited and heavily supervised. It is for state or tribal programs importing certain drugs from Canada under FDA authorization, not for a loose web of benefit vendors sourcing medicines through nonstandard channels (congress.gov, ecfr.gov). The difference between those two worlds is the whole story. In the legal Section 804 model, the sponsor has to show the drugs will lower costs without adding risk. The FDA requires drug-specific review, authenticity testing, relabeling to match U.S. labeling, quarterly reporting, supply-chain controls, recall procedures, and adverse-event monitoring. The agency’s own import rules are built around traceability. They assume regulators know what crossed the border, who handled it, and how to find it again if something goes wrong (fda.gov, fda.gov). AFPs cut across that design. CNBC’s reporting found that these programs connect patients to foreign sources for expensive medicines that their plans refuse to cover, even though regulators say those imports can violate federal law. The risk is not just that a product could be counterfeit or mishandled. It is that the paper trail itself may be broken. If a patient has a bad reaction, investigators may have to figure out which country the product came from, which intermediary touched it, whether the labeling matched the approved U.S. version, and whether the lot can even be identified with confidence. The FDA acknowledged that drugs that bypass safeguards may be contaminated, counterfeit, or contain the wrong amount of active ingredient. It still chose not to say more (cnbc.com). That silence is especially striking because the agency already knows how to speak clearly when it wants to. In January 2024, the FDA authorized Florida’s Section 804 importation program and laid out exact conditions for how it would work. Florida remains the only state with that authorization. Even then, authorization did not mean open borders for cheap drugs. The state still had to clear drug-specific submissions before importation, and by early 2026 the effort had largely stalled amid resistance from Canadian suppliers and questions about whether any shipments had actually begun (fda.gov, politico.com). So the FDA’s position is oddly precise in one corner and blurry in another. It can describe, in detail, the chain of custody required for a state-run Canadian import program. But when asked to clarify how the law applies to private benefit schemes that appear to bypass those controls, it stepped back. The result is a gray zone where the government warns that safeguards have been circumvented, yet declines to define the boundary any further than that (cnbc.com, fda.gov).